Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Jeil Pharmaceutical Co., Ltd.

Clinicaltrial registered26 Oct 2026

Jeil Pharmaceutical Co., Ltd.

26 Oct 2026: Trial registered · Post-Marketing Surveillance to Evaluate the Safety and Effectiveness of Zastaprazan Citrate. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
26 Oct 2026
Title
Post-Marketing Surveillance to Evaluate the Safety and Effectiveness of Zastaprazan Citrate
Conditions
Erosive Gastroesophageal Reflux Disease
Study Type
Observational
Status
Recruiting
Countries
South Korea
Country
South Korea
Reference
NCT07894939
Location
South Korea
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Jeil Pharmaceutical Co., Ltd.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for Jeil Pharmaceutical Co., Ltd. in our registers.

More from South Korea

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.